Comparing classifications of death in the Mode Selection Trial: Agreement and disagreement among site investigators and a clinical events committee

Contemporary Clinical Trials

Volumn 27, Issue 3, 2006, Pages 260-268

  Petersen, John L ^a   Haque, Ghazala ^a   Hellkamp, Anne S ^a   Flaker, Greg C ^b   Mark Estes III, N A ^c   Marchlinski, Francis E ^d   McAnulty, John H ^e   Greenspon, Arnold J ^f   Marinchak, Roger A ^g   Lee, Kerry L ^a   Lamas, Gervasio A ^h   Mahaffey, Kenneth W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e LEGACY HEALTH SYSTEM   (United States)

^f LANKENAU HOSPITAL   (United States)

^g THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^h Miami Heart Inst   (United States)

Author keywords

Classification of death; Clinical events committees; Endpoint adjudication; Mode Selection Trial; MOST

Indexed keywords

ARTICLE; CAUSE OF DEATH; CLASSIFICATION; CLINICAL RESEARCH; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DECISION MAKING; HUMAN; KAPPA STATISTICS; MAJOR CLINICAL STUDY; OBSERVER VARIATION; PHYSICIAN; SINUS NODE DYSFUNCTION;

CAUSE OF DEATH; CLINICAL TRIALS; CLINICAL TRIALS DATA MONITORING COMMITTEES; DECISION MAKING; HUMANS; INTERDISCIPLINARY COMMUNICATION; OBSERVER VARIATION; OUTCOME ASSESSMENT (HEALTH CARE); PEER REVIEW; RESEARCH PERSONNEL;

EID: 33646180879     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2006.02.002     Document Type: Article

References (22)

1. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 295-302
3. The Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 302 (1980) 250-256
4. Temple R., and Pledger G.W. The FDA's critique of the anturane reinfarction trial. N Engl J Med 303 (1980) 1488-1492
5. Every N.R., Parsons L., Hlatky M.A., et al. Use and accuracy of state death certificates for classification of sudden cardiac deaths in high-risk populations. Am Heart J 134 (1997) 1129-1132
6. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House Classification. EDTRS report number 10. Ophthalmology 98 (1991) 786-806
7. Lamas G.A., Lee K.L., Sweeney M., et al. For the mode selection trial in sinus-node dysfunction. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Eng J Med 346 (2002) 1854-1862
8. Lamas G.A., Lee K., Sweeney M., et al. The Mode Selection Trial (MOST) in sinus node dysfunction: design, rationale, and baseline characteristics of the first 1000 patients. Am Heart J 140 (2000) 541-551
9. Cicchetti D.V., and Allison T. A new procedure for assessing reliability of scoring EEG sleep recordings. Am J EEG Technol 11 (1971) 101-109
10. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273 (1995) 1450-1456
11. Cleland J.G., Erhardt L., Murray G., Hall A.S., and Ball S.G. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE study investigators. Eur Heart J 18 (1997) 41-51
12. O'Connor C.M., Carson P.E., Miller A.B., et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective randomized amlopidine survival evaluation. Am J Cardiol 82 (1998) 881-887
13. Cleland J.G., Erhardt L., Hall A.S., Winter C., and Ball S.G. Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: a report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. J Cardiovasc Pharmacol 22 9 (1993) S22-S27
14. Epstein A.E., Carlson M.D., Fogoros R.N., Higgins S.L., and Venditti Jr. F.J. Classification of death in antiarrhythmia trials. J Am Coll Cardiol 27 (1996) 433-442
15. Naslund U., Grip L., Fischer-Hansen J., et al. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: Results with and without the end-point committee's final decision on end-points. Eur Heart J 20 (1999) 771-777
16. Mahaffey K.W., Roe M.T., Dyke C.K., et al. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Am Heart J 143 (2002) 242-248
17. Narang R., Cleland J.G., Erhardt L., et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 17 (1996) 1390-1403
18. Harrington R.A., Lincoff A.M., Califf R.M., et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 25 (1995) 1693-1699
19. Maclure M., and Willett W.C. Misinterpretation and misuse of the kappa statistic. Am J Epidemiol 126 (1987) 161-169
20. Uretsky B.F., Thygesen K., Armstrong P.W., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 102 (2000) 611-616
21. Remington R.D. Who should code cause of death in a clinical trial?. Control Clin Trials 5 (1984) 241-244
22. Walter S.D., Cook D.J., Guyatt G.H., King D., and Troyan S. Outcome assessment for clinical trials: how many adjudicators do we need? Canadian lung oncology group. Control Clin Trials 18 (1997) 27-42